ICICI Direct rates Laurus Labs Ltd Buy
Laurus Labs carries a ₹2550 target, 15% upside, based on 38x FY29E EBITDA of ₹3686 crore, supported by sustained capex and consistent execution.
By ScoutQuest · · 2 min read
From the report
The figures below are as printed in the report by ICICI Direct.
- Rating
- Buy
- Target
- ₹ 2550
- Price at report
- ₹ 2215
- Upside to target
- 15.1%from the price at report, worked out from the two figures above
- Valuation
- 38 x · EV/EBITDA · FY29E
- Report
- company update
- Horizon
- 12 months
Target of ₹2555 is based on 38x FY29E EBITDA of ₹3686 crore, with the premium valuation justified by the sustained capex drive and consistent delivery of strong numbers.
Catalysts
The broker's points, summarised.
- CDMO commercial supply visibility over the next 18–24 months
- Peptide commercial revenues likely from around 2029
- Laurus Bio-4 commercial supplies from Q1FY28
- KRKA JV meaningful revenue contribution during FY28–FY29
- ₹3,000 crore capex guidance for FY27–FY28 tilted towards CDMO
Risks
The broker's points, summarised.
- Overall performance heavily dependent on CDMO success
- Non-ARV, Non-CDMO businesses remain volatile
Analysts: Siddhant Khandekar, Shubh Mehta, Vedant Nilekar
CDMO surge powers Q2FY27 performance
Laurus Labs' September quarter revenue rose ~33% YoY to ₹2206 crore, with the CDMO segment up ~86% YoY to ₹875 crore and now 39% of the mix. ICICI Direct notes this offset flat Generic API growth of 1% to ₹625 crore and a ~38% YoY decline in Laurus Bio to ₹29 crore.
Broad-based demand supports the CDMO run rate
The quarterly CDMO run rate has moved from ₹220–250 crore to roughly ₹800 crore in two years. About 55% of CDMO revenue came from commercial supplies and the rest from late-stage clinical work, which ICICI Direct sees as evidence the base is durable rather than one large order.
Margin improvement comes from mix and leverage
EBITDA reached ₹750 crore at a 34% margin, up 962 bps YoY, helped by a 314 bps YoY rise in gross margin to 63% and improving operating leverage. PAT stood at ₹437 crore for the quarter.
Capex stays heavily oriented to CDMO
Of the ₹5180 crore-plus spent in FY22–FY27, ~84% went to API and CDMO, and the ₹3000 crore incremental guidance for FY27–FY28 leans toward CDMO. The 530-acre Laurus Pharma Zone, with potential investment of ₹5630 crore in three phases, is flagged as a possible next leg of growth capex.
Management targets CDMO at half of revenue
The company has reiterated guidance of ~50% CDMO contribution by FY30, with focus on peptides, ADCs and gene therapies. ICICI Direct highlights a long pattern of sustained capex despite temporary slowdowns in reported numbers.
ICICI Direct's call
ICICI Direct maintains a BUY rating with a target price of ₹2550 over a 12-month horizon, implying 15% upside. The broker argues the premium valuation is justified by the company's continued capex drive and its track record of delivering strong numbers consistently. The target is derived from 38x FY29E EBITDA of ₹3686 crore.
Also from Laurus Labs
ICICI Securities rates Laurus Labs Ltd Buy
17 Nov 2026
Promoters sold 15,70,000 and 5,00,000 shares over two days, company clarifies
17 Nov 2026
Laurus Labs stock rallied after promoter stake sale clarified as being for philanthropic and debt repayment reasons, with business outlook unchanged
17 Nov 2026
The call above is ICICI Direct's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.